Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan maintains an Overweight rating on Health Catalyst (NASDAQ:HCAT) but lowers the price target from $14 to $11.
August 26, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains an Overweight rating on Health Catalyst but reduces the price target from $14 to $11, indicating a more cautious outlook.
The reduction in the price target from $14 to $11 suggests a more cautious outlook on Health Catalyst's stock performance, which may lead to short-term downward pressure on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100